title: Fucoidan prevents high-fat diet-induced obesity in animals by suppression of fat accumulation.
abstract: This study examines the antiobesity effects of fucoidan in an animal model of diet-induced obesity. Mice were fed a standard diet or high-fat diet (HFD) for 5 weeks. After that, the mice were divided into four experimental groups, with 10 mice per group, including a standard diet group, HFD group, HFD containing 1% fucoidan (HFD + FUCO 1%) group and HFD containing 2% fucoidan (HFD + FUCO 2%) group. The fucoidan supplementation group had significantly decreased body-weight gain, food efficiency ratio and relative liver and epididymal fat mass compared with the HFD group. The mice supplemented with fucoidan showed significantly reduced triglyceride, total cholesterol and low-density lipoprotein levels in the plasma. Liver steatosis induced by the HFD improved in the fucoidan-supplemented group. Furthermore, fucoidan affected the down-regulation expression patterns of epididymal adipose tissue genes such as peroxisome proliferator-activated receptor γ, adipose-specific fatty acid binding protein and acetyl CoA carboxylase. Therefore, fucoidan may be considered for use in improving obesity.
authors.affiliation: The Institute of Life Science, Sungkyunkwan University, 300 Cheoncheon-dong, Jangan-Gu, Gyeonggi-do, 440-746, Suwon, Republic of Korea.
authors.forename: Mi-Ja
authors.initials: MJ
authors.lastname: Kim
authors.forename: Joseph
authors.initials: J
authors.lastname: Jeon
authors.forename: Jin-Sil
authors.initials: JS
authors.lastname: Lee
mesh_terms: D000103:Acetyl-CoA Carboxylase / Q000235:genetics / Q000378:metabolism; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D059305:Diet, High-Fat / Q000009:adverse effects; D019587:Dietary Supplements; D015536:Down-Regulation / Q000187:drug effects; D004822:Epididymis / Q000187:drug effects; D050556:Fatty Acid-Binding Proteins / Q000235:genetics / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D047495:PPAR gamma / Q000235:genetics / Q000378:metabolism; D011134:Polysaccharides / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
chemical_list: D019440:Anti-Obesity Agents; D050556:Fatty Acid-Binding Proteins; D008077:Lipoproteins, LDL; D047495:PPAR gamma; D011134:Polysaccharides; D014280:Triglycerides; C007789:fucoidan; D002784:Cholesterol; D000103:Acetyl-CoA Carboxylase
keywords: antiobesity; fat accumulation; fucoidan; steatosis